Intech Investment Management LLC acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,322 shares of the company's stock, valued at approximately $367,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock worth $6,520,000 after buying an additional 24,043 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after purchasing an additional 3,518 shares during the last quarter. FMR LLC lifted its stake in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after purchasing an additional 601,611 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Enliven Therapeutics in the third quarter valued at approximately $5,998,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Enliven Therapeutics by 12.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after purchasing an additional 2,944 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on ELVN shares. HC Wainwright upped their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research report on Friday, March 21st. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Enliven Therapeutics currently has an average rating of "Buy" and an average price target of $38.75.
Get Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Price Performance
ELVN stock traded down $0.44 during mid-day trading on Friday, reaching $21.07. 192,187 shares of the company traded hands, compared to its average volume of 274,965. Enliven Therapeutics, Inc. has a 52-week low of $15.96 and a 52-week high of $30.03. The company has a market capitalization of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04. The company has a fifty day moving average price of $21.28 and a 200-day moving average price of $23.74.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Insiders Place Their Bets
In other news, insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the sale, the insider now owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. This trade represents a 1.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total value of $66,332.50. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $265,330. This represents a 20.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 70,434 shares of company stock worth $1,558,673 in the last ninety days. 29.20% of the stock is currently owned by insiders.
About Enliven Therapeutics
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
